NeuroSense Therapeutics : Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC – Form 6-K – Marketscreener.com

NeuroSense Therapeutics : Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC – Form 6-K – Marketscreener.com
Source: Google NewsPublished on 2022-06-01